tbuckley/cabot-search huggingface dataset:
Different Time Trends of Caloric and Fat Intake Between Statin Users and Nonusers Among US Adults
Authors: Takehiro Sugiyama, Yusuke Tsugawa, Chi-Hong Tseng, Yasuki Kobayashi, Martin F. Shapiro
Journal: JAMA Internal Medicine (2014)

Both dietary modification and use of statins can lower blood cholesterol. The increase in caloric intake among the general population is reported to have plateaued in the last decade, but no study has examined the relationship between the time trends of caloric intake and statin use.To examine the difference in the temporal trends of caloric and fat intake between statin users and nonusers among US adults.A repeated cross-sectional study in a nationally representative sample of 27,886 US adults, 20 years or older, from the National Health and Nutrition Examination Survey, 1999 through 2010.Statin use.Caloric and fat intake measured through 24-hour dietary recall. Generalized linear models with interaction term between survey cycle and statin use were constructed to investigate the time trends of dietary intake for statin users and nonusers after adjustment for possible confounders. We calculated model-adjusted caloric and fat intake using these models and examined if the time trends differed by statin use. Body mass index (BMI) changes were also compared between statin users and nonusers.In the 1999-2000 period, the caloric intake was significantly less for statin users compared with nonusers (2000 vs 2179 kcal/d; P = .007). The difference between the groups became smaller as time went by, and there was no statistical difference after the 2005-2006 period. Among statin users, caloric intake in the 2009-2010 period was 9.6% higher (95% CI, 1.8-18.1; P = .02) than that in the 1999-2000 period. In contrast, no significant change was observed among nonusers during the same study period. Statin users also consumed significantly less fat in the 1999-2000 period (71.7 vs 81.2 g/d; P = .003). Fat intake increased 14.4% among statin users (95% CI, 3.8-26.1; P = .007) while not changing significantly among nonusers. Also, BMI increased more among statin users (+1.3) than among nonusers (+0.4) in the adjusted model (P = .02).Caloric and fat intake have increased among statin users over time, which was not true for nonusers. The increase in BMI was faster for statin users than for nonusers. Efforts aimed at dietary control among statin users may be becoming less intensive. The importance of dietary composition may need to be reemphasized for statin users.
Inflammatory cells in the airways in COPD
Authors: R O'Donnell
Journal: Thorax (2006)

Airway inflammation is central to the pathogenesis of both airway remodelling and parenchymal destruction in chronic obstructive pulmonary disease (COPD). Neutrophils, macrophages, and CD8+ T lymphocytes have been implicated in a number of studies, but a detailed profile of disease-phenotype specific inflammation has yet to emerge. The heterogeneity of the disease has hindered data interpretation while extrapolation of the results of relatively non-invasive studies to the actual pathology found in the distal lung is difficult. Moreover, prominent studies have had frequently conflicting results. Further investigations are needed to marry the different clinical phenotypes of COPD to their respective inflammatory profiles in the airways and thus improve our understanding of the pathogenesis of the disease as a whole.
The 2013 EAU Guidelines on Chronic Pelvic Pain: Is Management of Chronic Pelvic Pain a Habit, a Philosophy, or a Science? 10 Years of Development
Authors: Daniel S. Engeler, Andrew P. Baranowski, Paulo Dinis-Oliveira, Suzy Elneil, John Hughes, Embert J. Messelink, Arndt van Ophoven, Amanda C. Williams
Journal: European Urology (2013)
Microarrays as Cancer Keys: An Array of Possibilities
Authors: Steve Mohr, George D. Leikauf, Gérard Keith, Bertrand H. Rihn
Journal: Journal of Clinical Oncology (2002)

Malignant transformation results from accumulation of genetic and epigenetic events. Functional studies of cancer will be crucial to our understanding of its complexity and polymorphism. There is no doubt that emerging genomic and proteomic technologies will facilitate such investigations. Microarray technology is a new and efficient approach to extract data of biomedical relevance for a wide range of applications. In cancer research, it will provide high-throughput and valuable insights into differences in an individual's tumor as compared with constitutional DNA, mRNA expression, and protein expression and activity. Across individuals, comparisons could provide tissue-specific disease signatures that provide diagnosis based on hundreds of informative genes. The resulting product should be a wealth of tumor-associated and tumor-specific biomarkers, which may help in cancer etiology, diagnosis, and therapy and ultimately lead to "molecular nosology" of cancers. This review highlights the recent developments in microarray technologies in cancer research, focuses on the results obtained so far, and describes the eventual use of microarray technology for clinical applications.
CD14+CD34 <sup>low</sup> Cells With Stem Cell Phenotypic and Functional Features Are the Major Source of Circulating Endothelial Progenitors
Authors: Paola Romagnani, Francesco Annunziato, Francesco Liotta, Elena Lazzeri, Benedetta Mazzinghi, Francesca Frosali, Lorenzo Cosmi, Laura Maggi, Laura Lasagni, Alexander Scheffold, Manuela Kruger, Stefanie Dimmeler, Fabio Marra, Gianfranco Gensini, Enrico Maggi, Sergio Romagnani
Journal: Circulation Research (2005)

Endothelial progenitor cells (EPCs) seem to be a promising tool for cell therapy of acute myocardial infarction, but their nature is still unclear. We show here that EPCs obtainable from peripheral blood (PB) derive from the adhesion-related selection in culture of a subset of CD14+ cells, which, when assessed by the highly-sensitive antibody-conjugated magnetofluorescent liposomes (ACMFL) technique, were found to express CD34. These CD14+CD34low cells represented a variable proportion at individual level of CD14+ cells, ranging from 0.6% to 8.5% of all peripheral-blood leukocytes, and constituted the dominant population among circulating KDR+ cells. By using the ACMFL technique, virtually all CD14+ cells present in the bone marrow were found to be CD14+CD34low double-positive cells. EPCs, as well as purified circulating CD14+CD34low cells, exhibited high expression of embryonic stem cell (SC) markers Nanog and Oct-4, which were downregulated in a STAT3-independent manner when they differentiated into endothelial cells (ECs). Moreover, circulating CD14+CD34low cells, but not CD14+CD34- cells, proliferated in response to SC growth factors, and exhibited clonogenicity and multipotency, as shown by their ability to differentiate not only into ECs, but also into osteoblasts, adipocytes, or neural cells. The results of this study may reconcile apparently contradictory data of the literature, showing the generation of PB-derived EPCs from either CD34+ or CD14+ cells. We suggest that the use of this previously unrecognized population of circulating CD14+CD34low cells, which exhibit both phenotypic and functional features of SCs, may be useful in improving cell-based therapies of vascular and tissue damage.
Developmental psychopathology: recent advances and future challenges
Authors: Seth D. Pollak
Journal: World Psychiatry (2015)

The integrative field of developmental psychopathology is having a huge impact on our understanding of human health and behavior. In this paper, I use the example of children's early stress exposure to illustrate how developmental psychopathologists now tend to deemphasize diagnostic categories and, instead, emphasize the social and biological contexts, events and circumstances that have created opportunities for maladaptive responses and health problems in youth. This example shows that developmental psychopathology is increasing understanding of how children develop the abilities that allow them to cope effectively with challenges and what leads to failures in development of these abilities. Integrating research about the neurobiology of learning may prove to be a powerful future direction to understand how the environment regulates behavior. Learning processes become increasingly intricate and fine-tuned as relevant neuroanatomical systems develop, and as the range, complexity and amount of environmental information increases for the developing child. A focus on these processes allows psychopathologists to formulate questions about which neural mechanisms children use to process information, how these mechanisms are themselves shaped by social context, why adverse social environments confer risk for children, and, perhaps, what sorts of neutrally informed interventions might remediate the deficits in self-regulation that underlie common psychopathologies.
Loperamide Therapy for Acute Diarrhea in Children: Systematic Review and Meta-Analysis
Authors: Su-Ting T Li, David C Grossman, Peter Cummings
Journal: PLoS Medicine (2007)

Background Loperamide is widely used in adults for acute diarrhea. However, its use in children has been discouraged by the World Health Organization and the American Academy of Pediatrics owing to concerns over safety and efficacy in young children. Methods and Findings To assess the efficacy and adverse effects of loperamide compared with placebo for acute diarrhea in children, we reviewed Medline, EMBase, the Cochrane Central Register of Controlled Trials, and bibliographies of known clinical trials and of review articles, and we also interviewed key investigators in the field. We undertook a systematic review and meta-analysis of randomized controlled trials of children younger than 12 y of age with acute diarrhea, comparing loperamide with placebo. Included trials reported data on diarrhea duration or severity, or provided data on adverse effects. Compared with patients who received placebo, patients allocated to loperamide were less likely to continue to have diarrhea at 24 h (prevalence ratio 0.66, 95% confidence interval [CI]: 0.57 to 0.78), had a shorter duration of diarrhea by 0.8 d (95% CI: 0.7 to 0.9 d), and had a lower count of stools at 24 h (0.84, 95% CI: 0.77 to 0.92). Results were similar when random-effects summaries were estimated. Serious adverse events, defined as ileus, lethargy, or death, were reported in eight out of 927 children allocated to loperamide (0.9%, 95% CI: 0.4% to 1.7%). Serious adverse events were not reported in any of the 764 children allocated to placebo (0%, 95% CI: 0% to 0.5%). Among the children allocated to loperamide, serious adverse events were reported only among children younger than 3 y. Conclusions In children who are younger than 3 y, malnourished, moderately or severely dehydrated, systemically ill, or have bloody diarrhea, adverse events outweigh benefits even at doses ≤0.25 mg/kg/d. In children who are older than 3 y with no/minimal dehydration, loperamide may be a useful adjunct to oral rehydration and early refeeding.
Sputum IL-6 concentrations in severe asthma and its relationship with FEV1
Authors: J. B. Morjaria, K. S. Babu, P. Vijayanand, A. J. Chauhan, D. E. Davies, S. T. Holgate
Journal: Thorax (2010)

As asthma becomes more severe it adopts additional characteristics including corticosteroid refractoriness and a neutrophil-predominant inflammatory response implicating Th1 or Th17 responses involving cytokines such as tumour necrosis factor α, interleukin (IL)-6 and IL-8. We have examined the role of IL-6 and IL-8 in severe asthma. Subjects with severe asthma (GINA stage IV) who were exacerbation-free for ≥4 weeks with a forced expiratory volume in 1 s (FEV1) >30% but <80% predicted were studied from the baseline parameters of a clinical trial.1 Cell counts and cytokines were measured in induced sputum (see online supplement for Methods).

Eighteen subjects (9M, 9F) with severe asthma (mean±SD age 43.4±11.4 years (1SD), FEV1 59±14% predicted) were studied (see table 1 in online appendix). The median (IQR) levels of sputum IL-8, IL-6, neutrophils (%), macrophages (%) and eosinophils (%) were 1853.8 pg/ml (1376.8–2537.7), 70.0 pg/ml (28.55–127.5), 32.5% (24.1–42.6), 46.8% (39.8–54.8) and 4.4% (3.2–9.4), respectively. We observed significant negative correlations between FEV1 …
Retinopathy in Diabetes
Authors: Donald S. Fong, Lloyd Aiello, Thomas W. Gardner, George L. King, George Blankenship, Jerry D. Cavallerano, Fredrick L. Ferris, Ronald Klein
Journal: Diabetes Care (2004)

Diabetic retinopathy is the most frequent cause of new cases of blindness among adults aged 20 –74 years. During the first two decades of disease, nearly all patients with type 1 diabetes and 60% of patients with type 2 diabetes have retinopathy. In the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), 3.6% of younger-onset patients (type 1 diabetes) and 1.6% of olderonset patients (type 2 diabetes) were legally blind. In the younger-onset group, 86% of blindness was attributable to diabetic retinopathy. In the older-onset group, in which other eye diseases were common, one-third of the cases of legal blindness were due to diabetic retinopathy. NATURAL HISTORY OF DIABETIC RETINOPATHY Diabetic retinopathy progresses from mild nonproliferative abnormalities, characterized by increased vascular permeability, to moderate and severe nonproliferative d iabetic r etinopathy (NPDR), characterized by vascular closure, to proliferative diabetic retinopathy (PDR), characterized by the growth of new blood vessels on the retina and posterior surface of the vitreous. Macular edema, characterized by retinal thickening from leaky blood vessels, can develop at all stages of retinopathy. Pregnancy, puberty, blood glucose control, hypertension, and cataract surgery can accelerate these changes. Vision-threatening retinopathy is rare in type 1 diabetic patients in the first 3–5 years of diabetes or before puberty. During the next two decades, nearly all type 1 diabetic patients develop retinopathy. Up to 21% of patients with type 2 diabetes have retinopathy at the time of first diagnosis of diabetes, and most develop some degree of retinopathy over time. Vision loss due to diabetic retinopathy results from several mechanisms. Central vision may be impaired by macular edema or capillary nonperfusion. New blood vessels of PDR and contraction of the accompanying fibrous tissue can distort the retina and lead to tractional retinal detachment, producing severe and often irreversible vision loss. In addition, the new blood vessels may bleed, adding the further complication of preretinal or vitreous hemorrhage. Finally, neovascular glaucoma associated with PDR can be a cause of visual loss.
MECHANISM OF ACTIVATION OF THE BONE MARROW-DERIVED LYMPHOCYTE
Authors: John W. Schrader
Journal: The Journal of Experimental Medicine (1973)

Peritoneal exudate cells from nu/nu mice stimulated with proteose peptone broth, but in general not from unstimulated mice, permitted cultures of spleen cells from congenitally athymic (nu/nu) mice to respond to the thymus-dependent antigen fowl gamma globulin (FgammaG). Supernatants of cultures of peritoneal cells were also effective, the activity being sensitive to trypsin. Since nu/nu mice were effective sources of the peritoneal cells it would not seem obligatory for the thymus-derived (T) cell to be involved in the triggering of the bone marrow-derived (B) cell by a thymus-dependent antigen FgammaG. It is proposed that the B cell is triggered at the macrophage surface where it encounters two signals (a) the antigen and (b) a protein secreted by the activated macrophage. In vivo the T cell may have a role in B-cell triggering, either in activating the macrophage or in aiding in presentation of antigen on the macrophage surface. Thymus-independent antigens are proposed to induce an IgM response because they are able to provide "signal two" either by direct interaction with the B cell or via irritation or activation of the macrophage. The stimulatory effect of T cells activated by an allogeneic interaction was used as a model of one influence of the T cell on the development of an antibody response. The presence in cultures of nu/nu spleen of an allogeneic interaction had no effect on the inability of these cells to respond to FgammaG. However when a source of the postulated second signal such as the supernatant of a macrophage culture was present, an allogeneic interaction had a powerful amplifying effect on the anti-FgammaG response. In contrast the response of nu/nu spleen cultures to heterologous erythrocytes was greatly enhanced by the presence of an allogeneic interaction. It is suggested that since there was a definite basal response to the heterologous erythrocytes added alone, the enhancement represented not an activation of more B cells but rather an amplification of this basal response. Thus the anti-FgammaG response in cultures of nu/nu spleen differentiates between factors such as those released by activated macrophages that are involved in B-cell triggering and factors released by activated T cells that amplify the numbers of antibody-forming cells resulting from a B cell already triggered.
Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study
Authors: Jacques Grill, Birgit Geoerger, Lyle Gesner, Danuta Perek, Pierre Leblond, Adela Cañete, Isabelle Aerts, Luis Madero, Josep Sanchez de Toledo Codina, Joris Verlooy, Edward Estlin, Laura Cisar, Aurora Breazna, Andrew Dorman, Simon Bailey, Gary Nicolin, Richard G Grundy, Darren Hargrave
Journal: Neuro-Oncology (2013)

This multicenter phase II study investigated temozolomide + irinotecan (TEMIRI) treatment in children with relapsed or refractory medulloblastoma.Patients received temozolomide 100-125 mg/m(2)/day (days 1-5) and irinotecan 10 mg/m(2)/day (days 1-5 and 8-12) every 3 weeks. The primary endpoint was tumor response within the first 4 cycles confirmed ≥4 weeks and assessed by an external response review committee (ERRC). In a 2-stage Optimum Simon design, ≥6 responses in the first 15 evaluable patients were required within the first 4 cycles for continued enrollment; a total of 19 responses from the first 46 evaluable patients was considered successful.Sixty-six patients were treated. Seven responses were recorded during stage 1 and 15 in the first 46 ERRC evaluated patients (2 complete responses and 13 partial responses). The objective response rate during the first 4 cycles was 32.6% (95% confidence interval [CI], 19.5%-48.0%). Median duration of response was 27.0 weeks (7.7-44.1 wk). In 63 patients evaluated by local investigators, the objective response rate was 33.3% (95% CI, 22.0%-46.3%), and 68.3% (95% CI, 55.3%-79.4%) experienced clinical benefit. Median survival was 16.7 months (95% CI, 13.3-19.8). The most common grade 3 treatment-related nonhematologic adverse event was diarrhea (7.6%). Grade 3/4 treatment-related hematologic adverse events included neutropenia (16.7%), thrombocytopenia (12.1%), anemia (9.1%), and lymphopenia (9%).The planned study primary endpoint was not met. However, its tolerability makes TEMIRI a suitable candidate chemotherapy backbone for molecularly targeted agents in future trials in this setting.
Brief Intervention for Patients With Problematic Drug Use Presenting in Emergency Departments
Authors: Michael P. Bogenschutz, Dennis M. Donovan, Raul N. Mandler, Harold I. Perl, Alyssa A. Forcehimes, Cameron Crandall, Robert Lindblad, Neal L. Oden, Gaurav Sharma, Lisa Metsch, Michael S. Lyons, Ryan McCormack, Wendy Macias Konstantopoulos, Antoine Douaihy
Journal: JAMA Internal Medicine (2014)

Medical treatment settings such as emergency departments (EDs) present important opportunities to address problematic substance use. Currently, EDs do not typically intervene beyond acute medical stabilization.
Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial
Authors: Arto A Palmu, Jukka Jokinen, Heta Nieminen, Hanna Rinta-Kokko, Esa Ruokokoski, Taneli Puumalainen, Dorota Borys, Patricia Lommel, Magali Traskine, Marta Moreira, Lode Schuerman, Terhi M Kilpi
Journal: The Lancet Infectious Diseases (2013)
Characterization of a Hemoglobin Protease Secreted by the Pathogenic <i>Escherichia coli</i> Strain EB1
Authors: Ben R. Otto, Silvy J.M. van Dooren, Jan H. Nuijens, Joen Luirink, Bauke Oudega
Journal: The Journal of Experimental Medicine (1998)

Many pathogenic bacteria can use heme compounds as a source of iron. Pathogenic Escherichia coli strains are capable of using hemoglobin as an iron source. However, the mechanism of heme acquisition from hemoglobin is not understood for this microorganism. We present the first molecular characterization of a hemoglobin protease (Hbp) from a human pathogenic E. coli strain. The enzyme also appeared to be a heme-binding protein. Affinity purification of this bifunctional protein enabled us to identify the extracellular gene product, and to clone and analyze its gene. A purification procedure developed for Hbp allowed us to perform functional studies. The protein interacted with hemoglobin, degraded it and subsequently bound the released heme. These results suggest that the protein is involved in heme acquisition by this human pathogen. Hbp belongs to the so-called IgA1 protease-like proteins, as indicated by the kinetics of its membrane transfer and DNA sequence similarity. The gene of this protein appears to be located on the large pColV-K30 episome, that only has been isolated from human and animal pathogens. All these characteristics indicate that Hbp may be an important virulence factor that may play a significant role in the pathogenesis of E. coli infections.
Treatment of COPD: the sooner the better?
Authors: M. Decramer, C. B. Cooper
Journal: Thorax (2010)

Classical belief is that only smoking cessation, and not pharmacotherapy, beneficially affect disease progression in chronic obstructive pulmonary disease (COPD). In recent years, new data on pharmacotherapy of COPD became available that shed new light on this question. The present paper reviews these data critically in an attempt to put them in a proper perspective. The most impressive new data are subgroup analyses of two large-scale long-term trials. With these new data it is now clear that patients in GOLD (Global Initiative for Chronic Obstructive Pulmonary Disease) stage II benefit as much from pharmacotherapy as patients in the later stages of the disease. Effects on prebronchodilator and postbronchodilator forced expiratory volume in 1 s (FEV(1)), health-related quality of life, exacerbations and hospitalisations appear at least as pronounced in GOLD stage II as in the other GOLD stages. In addition, evidence suggestive of an effect on disease progression is available in the sense of an effect on rate of decline of FEV(1), and trends for reductions in mortality. Finally, good evidence is available that, in contrast to conventional thinking, decline of FEV(1) occurs at a considerably faster rate in the early stages of the disease. These data together with the high prevalence of co-morbidities from early in the disease onwards provide us with strong suggestive evidence for early intensive intervention in COPD. New trials, particularly demonstrating the detrimental effects of delaying treatment until later in the course of the disease, are required to render the evidence for early intensive intervention irrefutable.